Patents Assigned to Merck
  • LIQUID CRYSTAL MEDIUM
    Publication number: 20180223187
    Abstract: The present invention relates to a liquid-crystalline medium (LC medium) which is distinguished by the fact that it comprises one or more compounds of the formula 1 and one or more compounds of the formula 2 and one or more compounds selected from formulae 3, 4 and 5, in which the individual radicals have the meanings according to Claim 1, and to the use thereof for electro-optical purposes and to LC displays containing this medium.
    Type: Application
    Filed: July 22, 2016
    Publication date: August 9, 2018
    Applicant: MERCK PATENT GMBH
    Inventors: Harald HIRSCHMANN, Andreas POHLE, Sabine SCHOEN
  • METHODS FOR MAKING PHARMACEUTICAL SOLID DOSAGE FORMS OF SPRAY-DRIED DISPERSIONS
    Publication number: 20180221282
    Abstract: A process for drying a spray dried dispersion, comprising: a) providing a spray-dried dispersion comprising particles wherein the particles comprise an active agent and a polymer and optionally one or more surfactants, the dispersion having an average particle diameter of less than about 100 m; b) blending an amount of silicon dioxide with the dispersion to form a dispersion-silicon dioxide blend, wherein the amount of silicon dioxide relative to the amount of dispersion is between about 0.5 and 2.0% by weight; c) drying the blend with a secondary dryer.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 9, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yung-Chi Lee, David Harris, Justin David Moser, Michael McNevin, Amber Broadbent, Robert Hall, Ari Ericson
  • PROCESS FOR PRODUCING CELL CULTURE MEDIA
    Publication number: 20180223250
    Abstract: The present invention relates to a process for manufacturing dry powder cell culture media. The preparation and usage of mixed particles generated by co-lyophilisation leads to cell culture media with improved solubility without changing the chemical composition.
    Type: Application
    Filed: July 8, 2016
    Publication date: August 9, 2018
    Applicant: Merck Patent GmbH
    Inventors: Joerg VON HAGEN, Nikolai STANKIEWICZ, Anke SIMON
  • ELECTROLUMINESCENT BRIDGED METAL COMPLEXES FOR USE IN ELECTRONIC DEVICES
    Publication number: 20180226591
    Abstract: The present invention relates to metal complexes and to electronic devices, especially organic electroluminescent devices, comprising these metal complexes.
    Type: Application
    Filed: July 4, 2016
    Publication date: August 9, 2018
    Applicant: Merck Patent GmbH
    Inventors: Philipp STOESSEL, Christian EHRENREICH
  • COMPOUNDS HAVING FLUORENE STRUCTURES
    Publication number: 20180226587
    Abstract: The present invention describes fluorene derivatives substituted by electron-transporting groups, especially for use as triplet matrix materials in electronic devices. The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.
    Type: Application
    Filed: July 28, 2016
    Publication date: August 9, 2018
    Applicant: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Thomas Eberle, Anja Jatsch, Tobias Grossmann, Jonas Valentin Kroeber
  • MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES
    Publication number: 20180222872
    Abstract: Fluorene derivatives that are connected in one or more of the 1-, 1?-, 4-, or 4?-positions in any combination to a carbon atom of a diaryl substituted triazinyl or pyrimidinyl derivative. The fluorene derivatives are not spirobifluorene derivatives. The compounds are suitable for use in electronic devices, in particular organic electroluminescent devices, comprising these compounds. In some embodiments, the compounds are used as matrix materials for phosphorescent or fluorescent emitters as well as a hole-blocking or an electron-transport layer.
    Type: Application
    Filed: July 1, 2016
    Publication date: August 9, 2018
    Applicant: Merck Patent GmbH
    Inventors: Anja Jatsch, Amir Hossain Parham, Thomas Eberle, Tobias Grossmann, Jonas Valentin Kroeber
  • LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY
    Publication number: 20180223189
    Abstract: The present invention relates to mesogenic media and to electro-optical displays comprising these media as light modulation media. In particular, the electro-optical displays according to the present invention are displays, which are operated at a temperature, at which the mesogenic modulation media are in an optically isotropic phase, preferably in a blue phase.
    Type: Application
    Filed: July 12, 2016
    Publication date: August 9, 2018
    Applicant: MERCK PATENT GMBH
    Inventors: Michael WITTEK, Mathias BREMER, Edward PLUMMER, Mila FISCHER, Harald LANNERT, Volker MEYER
  • COLOURING OF SURFACES
    Publication number: 20180223103
    Abstract: The present invention relates to a process for colouring surfaces, in particular surfaces of foods, with effect pigments, preferably pearlescent pigments, based on flake-form substrates, where (i) the effect pigment is incorporated into a pasty, transparent, water-based material and (ii) the application medium prepared in step (i) is applied to the surface.
    Type: Application
    Filed: February 7, 2018
    Publication date: August 9, 2018
    Applicant: Merck Patent GmbH
    Inventor: Ralf SCHWEINFURTH
  • PREPARATION AND COLOURING OF PULVERULENT FOODS
    Publication number: 20180220685
    Abstract: A process for the preparation and colouring of pulverulent foods which is distinguished by the fact that uncoloured pulverulent foods are mixed with effect pigments based on flake-form substrates.
    Type: Application
    Filed: February 7, 2018
    Publication date: August 9, 2018
    Applicant: MERCK PATENT GMBH
    Inventors: Alexander PETERS, Ralf SCHWEINFURTH
  • Multi-element standard for nuclear magnetic resonance spectroscopy
    Patent number: 10040811
    Abstract: Organic compounds which contain nitrogen, fluorine, and phosphorus atoms together with carbon atoms and hydrogen atoms and which can be used as a multi-element standard for 1H—, 13C—, 15N—, 19F—, and 31P nuclear magnetic resonance spectroscopy. Also, a nuclear magnetic resonance spectroscopy method, preferably a quantitative nuclear magnetic resonance spectroscopy method, using said compounds and a method for qualitatively and/or quantitatively determining an analyte using such a nuclear magnetic resonance spectroscopy method.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 7, 2018
    Assignee: Merck Patent GmbH
    Inventor: Bernd Willi Karl-Heinz Diehl
  • Pyrrolopyridazine inhibitors of IRAK4 activity
    Patent number: 10040798
    Abstract: The present invention relates to pyrrolopyridazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: August 7, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jongwon Lim, Michael D. Altman, Jason D. Brubaker, Craig R. Gibeau
  • Substituted imidazo[1,5-a]pyrazines as Btk inhibitors
    Patent number: 10040805
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, Formula (I) or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: August 7, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jian Liu, Joseph A. Kozlowski, Xiaolei Gao, Deodial Guy Guiadeen, Shilan Liu, Dahai Wang
  • Electrically conductive pigment
    Patent number: 10040963
    Abstract: The present invention relates to electrically conductive pigments, to a process for the preparation thereof and to the use thereof, in particular in antistatic or dissipative articles or surfaces, for example in paints, coatings, printing inks or floorcoverings.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: August 7, 2018
    Assignee: Merck Patent GmbH
    Inventors: Reinhold Rueger, Bjoern Kleist
  • Thienopyrazine inhibitors of IRAK4 activity
    Patent number: 10040802
    Abstract: The present invention relates to thienopyrazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: August 7, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jongwon Lim, Michael D. Altman, Craig R. Gibeau
  • METHOD FOR INCREASING THE GLUTATHIONE LEVEL IN CELLS
    Publication number: 20180216061
    Abstract: The present invention relates to the use of sulfocysteine and derivatives thereof to increase the gluthathione pool in cells.
    Type: Application
    Filed: July 1, 2016
    Publication date: August 2, 2018
    Applicant: Merck Patent GmbH
    Inventor: Aline ZIMMER
  • ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS
    Publication number: 20180215808
    Abstract: The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.
    Type: Application
    Filed: March 22, 2018
    Publication date: August 2, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Kalpit A. Vora, Kara S. Cox, Aimin Tang, Zhifeng Chen, Daniel DiStefano, Lan Zhang, Hua-Poo Su
  • ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS
    Publication number: 20180215809
    Abstract: The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.
    Type: Application
    Filed: March 22, 2018
    Publication date: August 2, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Kalpit A. Vora, Kara S. Cox, Aimin Tang, Zhifeng Chen, Daniel DiStefano, Lan Zhang, Hua-Poo Su
  • AZA-CYANOQUINOLINONE PDE9 INHIBITORS
    Publication number: 20180214439
    Abstract: The present invention is directed to azacyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: July 27, 2016
    Publication date: August 2, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: ANTONELLA CONVERSO, KEVIN RODZINAK
  • LUMINESCENT PARTICLE, INK FORMULATION, POLYMER COMPOSITION, OPTICAL DEVICE, FABRICATION OF THEREOF, AND USE OF THE LUMINESCENT PARTICLE
    Publication number: 20180215998
    Abstract: The present invention relates to a luminescent particle, ink formulation, polymer composition, optical device and a preparation thereof. The invention further relates to use of a luminescent particle in a medium or biological imaging.
    Type: Application
    Filed: June 29, 2016
    Publication date: August 2, 2018
    Applicant: MERCK PATENT GMBH
    Inventors: Yuki HIRAYAMA, Hiroshi OKURA, Stephan DERTINGER, Yoshio KOBAYASHI
  • ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS
    Publication number: 20180215810
    Abstract: The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.
    Type: Application
    Filed: March 22, 2018
    Publication date: August 2, 2018
    Applicant: Merck Sharp & Dahme Corp.
    Inventors: Kalpit A. Vora, Kara S. Cox, Aimin Tang, Zhifeng Chen, Daniel DiStefano, Lan Zhang, Hua-Poo Su